secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0000950170-23-046572
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports preclinical data: PGN-EDODM1 corrects 99% of mis-splicing in DM1 mouse model
--------------------------------------------------------------------------------

- EDO platform delivers 25-fold higher oligonucleotide to myotube nuclei vs naked in vitro.
- 72% of skeletal muscle nuclei in NHPs positive for oligo after two 30 mg/kg doses.
- Single dose of PGN-EDODM1 reversed 76% myotonia and corrected 68% mis-splicing in DM1 mouse.
- Four doses reversed 99% myotonia and corrected 99% mis-splicing; well-tolerated.
- PGN-EDO51 safety in humans: transient, mild, reversible TEAEs at 5 and 10 mg/kg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/0000950170-23-046572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/pepg-20230906.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-046572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer